ArticleCureus2025
Factors Affecting Patency of Uncovered Duodenal Stents in Malignant Duodenal Stenosis Due to Pancreatic Cancer: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Malignant duodenal stenosis is a common complication in patients with pancreatic cancer, significantly impairing quality of life by obstructing oral intake. Duodenal stenting has become a preferred palliative intervention, offering minimally invasive symptom relief and allowing for the continuation of systemic chemotherapy. However, factors influencing stent patency remain underexplored. This study aimed to identify clinical, procedural, and tumor-related factors that affect the patency of uncovered duodenal stents in malignant duodenal stenosis caused by pancreatic cancer. Methods A retrospective cohort study was conducted at Chiba University Hospital, Chiba, Japan, analyzing data from 53 patients who underwent placement of 22 mm uncovered duodenal stents between June 2016 and December 2023. Eligibility criteria included that the primary tumor had not been resected and that no intestinal reconstruction had been performed. Data on patient demographics, tumor characteristics, procedural details, and outcomes were collected. Univariate and multivariate analyses were performed to evaluate factors influencing stent patency using the Kaplan-Meier method and Cox proportional hazards modeling. Results The mean patency duration for uncovered duodenal stents was 474 days, with stent occlusion occurring in 11 (20.8%) patients. Univariate analysis identified prior placement of transpapillary biliary plastic stents as significantly associated with reduced stent patency (p = 0.0057). Multivariate analysis confirmed this as an independent predictor of shorter patency (hazard ratio, 5.75; 95% CI, 1.37-24.22; p = 0.017). Tumor size, chemotherapy administration, and the location of duodenal stenosis were not significantly associated with stent patency. Conclusions Prior placement of transpapillary biliary plastic stents significantly reduces the patency of uncovered duodenal stents in patients with malignant duodenal stenosis caused by pancreatic cancer. This underscores the importance of procedural planning, including consideration of alternative biliary drainage methods, to optimize stent performance and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.